InSilico Medicine Cayman TopCo revenue and financials
In the fiscal year ended December 2025, InSilico Medicine Cayman TopCo reported revenue of $56.24M (−34.48% year over year). The net loss was $352.32M.
Fiscal year ending in December. Sources and method on the page How we analyse stocks.
At a glance
- Revenue growth
- −34.48%
- 2025 vs 2024
- Net margin
- -626.5%
- 2024: -19.9%
How InSilico Medicine Cayman TopCo is changing
Calculated from the annual statements; each fiscal year is labelled with the year it ends.
Revenue grew 23.1% a year on average over the last 3 years
Compound annual growth rate: from $30.15M in 2022 to $56.24M in 2025.
Operating margin rose from −265.8% to −106.7%
Operating income over revenue, 2022 → 2025: 159.1 percentage points.
Shares outstanding up 17.4% in 3 years
Average diluted shares, 2022 → 2025: with more shares, each one represents a smaller stake in the company (dilution).
Profitable in 0 of 4 fiscal years
Positive net income, fiscal years 2022–2025.
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | 56.2 | 85.8 | 51.2 | 30.1 |
| Cost of revenue | 10.4 | 8.3 | 12.6 | 11.0 |
| Gross profit | 45.8 | 77.6 | 38.6 | 19.1 |
| Selling, general and administrative | 23.7 | 23.0 | 25.1 | 20.8 |
| Research and development | 81.4 | 91.9 | 97.3 | 78.2 |
| Operating income | -60.0 | -37.3 | -83.7 | -80.1 |
| EBIT | -60.0 | -37.3 | -83.7 | -80.1 |
| EBITDA | -57.3 | -32.9 | -80.6 | -79.4 |
| Interest expense | 0.2 | 0.1 | 0.1 | 0.1 |
| Pre-tax income | -352 | -16.9 | -212 | -222 |
| Income tax | 0.1 | 0.2 | 0.1 | 0.0 |
| Net income | -352 | -17.1 | -212 | -222 |
| Net income to common shareholders | -352 | -17.1 | -212 | -222 |
| Basic EPS | -4.48 | -0.24 | -3.13 | -3.31 |
| Diluted EPS | -4.48 | -0.24 | -3.13 | -3.31 |
| Average shares (basic) | 78.7 | 71.8 | 67.6 | 67.1 |
| Average shares (diluted) | 78.7 | 71.8 | 67.6 | 67.1 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|---|
| Total revenue | 106 | 28.8 | 27.5 | 26.1 | 59.7 |
| Cost of revenue | 10.3 | 6.0 | 4.4 | 4.4 | 3.9 |
| Gross profit | 96.0 | 22.8 | 23.0 | 21.8 | 55.8 |
| Selling, general and administrative | 18.9 | 14.1 | 9.6 | 15.5 | 7.5 |
| Research and development | 49.3 | 45.8 | 35.6 | 46.3 | 45.6 |
| Operating income | 28.3 | -37.6 | -22.4 | -39.9 | 2.5 |
| EBIT | 28.3 | -37.6 | -22.4 | -39.9 | 2.5 |
| EBITDA | 29.8 | -36.2 | -21.1 | -37.5 | 4.6 |
| Interest expense | 0.2 | 0.1 | 0.1 | 0.1 | 0.0 |
| Pre-tax income | 35.8 | -333 | -19.2 | -25.0 | 8.1 |
| Income tax | 0.3 | 0.0 | 0.0 | 0.1 | 0.1 |
| Net income | 35.5 | -333 | -19.2 | -25.1 | 8.0 |
| Net income to common shareholders | 35.5 | -333 | -19.2 | -25.1 | 8.0 |
| Basic EPS | 0.06 | -4.16 | -0.25 | -0.33 | 0.12 |
| Diluted EPS | 0.06 | -4.16 | -0.25 | -0.35 | 0.11 |
| Average shares (basic) | 573 | 80.1 | 77.3 | 76.1 | 67.6 |
| Average shares (diluted) | 601 | 80.1 | 77.3 | 76.1 | 84.4 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total assets | 490 | 144 | 203 | 235 |
| Current assets | 474 | 133 | 189 | 219 |
| Cash and equivalents | 393 | 126 | 177 | 208 |
| Short-term investments | 53.9 | — | — | — |
| Receivables | 24.9 | 4.7 | 4.9 | 6.3 |
| Net property, plant and equipment | 13.2 | 9.4 | 12.8 | 14.3 |
| Other intangible assets | 0.3 | 0.3 | 0.4 | 0.2 |
| Long-term investments | 0.7 | 0.2 | 0.4 | 1.0 |
| Current liabilities | 33.9 | 807 | 852 | 682 |
| Accounts payable | 13.6 | 18.0 | 17.8 | 19.1 |
| Total debt | 6.0 | 2.6 | 2.2 | 3.2 |
| Total liabilities | 38.0 | 808 | 853 | 684 |
| Total equity (incl. minority) | 452 | -664 | -650 | -450 |
| Retained earnings | -1,033 | -681 | -663 | -452 |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|---|
| Total assets | 620 | 490 | 241 | 144 | — |
| Current assets | 601 | 474 | 226 | 133 | — |
| Cash and equivalents | 358 | 393 | 213 | 126 | — |
| Short-term investments | 109 | 53.9 | — | — | — |
| Receivables | 12.2 | 24.9 | 10.1 | 4.7 | — |
| Net property, plant and equipment | 11.8 | 13.2 | 13.6 | 9.4 | — |
| Other intangible assets | 0.2 | 0.3 | 0.3 | 0.3 | — |
| Long-term investments | 5.1 | 0.7 | 0.7 | 0.2 | — |
| Current liabilities | 69.1 | 33.9 | 918 | 807 | — |
| Accounts payable | 11.4 | 13.6 | 15.2 | 18.0 | — |
| Total debt | 5.0 | 6.0 | 6.9 | 2.6 | — |
| Total liabilities | 72.6 | 38.0 | 923 | 808 | — |
| Total equity (incl. minority) | 547 | 452 | -681 | -664 | — |
| Retained earnings | -997 | -1,033 | -700 | -681 | — |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Operating cash flow | -76.8 | -57.4 | -29.6 | -47.5 |
| Depreciation and amortization | 4.8 | 6.0 | 4.5 | 1.8 |
| Capital expenditure | -2.9 | -0.8 | -2.6 | -11.0 |
| Investing cash flow | -50.3 | 7.4 | 0.7 | -13.6 |
| Financing cash flow | 394 | -1.5 | -2.2 | 107 |
| Debt repaid | -2.1 | -1.6 | -1.4 | -1.0 |
| Effect of exchange rates | 0.7 | 0.3 | 0.4 | 0.3 |
| Net change in cash | 267 | -51.2 | -30.7 | 46.3 |
| Free cash flow | -79.6 | -58.2 | -32.1 | -58.5 |
| Levered free cash flow | -821 | -56.4 | 129 | — |
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q4 2025 | Q2 2025 | Q4 2024 | Q2 2024 |
|---|---|---|---|---|---|
| Operating cash flow | 79.0 | -39.9 | -36.8 | -25.0 | -32.4 |
| Depreciation and amortization | 2.5 | 2.5 | 2.3 | 3.2 | 2.8 |
| Capital expenditure | -0.9 | -1.9 | -0.9 | 0.0 | -0.9 |
| Investing cash flow | -171 | -52.7 | 2.4 | 15.9 | -8.4 |
| Financing cash flow | 55.1 | 273 | 120 | -0.7 | -0.9 |
| Debt issued | 17.5 | — | — | — | — |
| Debt repaid | -3.7 | -1.1 | -1.0 | -0.8 | -0.8 |
| Effect of exchange rates | 1.4 | 0.5 | 0.2 | -0.0 | 0.3 |
| Net change in cash | -35.7 | 181 | 86.2 | -9.8 | -41.4 |
| Free cash flow | 78.1 | -41.9 | -37.8 | -25.0 | -33.3 |
| Levered free cash flow | 66.6 | -916 | 93.6 | -56.4 | — |
Financial statements of similar companies
Companies in the group: same industry, similar size
